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Stefan Wagenpfeil, PhD; Michael B€ohm, MD; Felix Mahfoud, MD
Background-—Central arteriovenous fistula (AVF) creation is under investigation for treatment of severe hypertension. We
evaluated the effects of AVF for initiation of hemodialysis on systolic, diastolic, and mean arterial blood pressure in patients with
end-stage renal disease.
Methods and Results-—Data search included PubMed, Web of Science, and the Cochrane Library. A systematic review and meta-
analysis of peer-reviewed studies reporting the effects of the creation/ligation of an AVF on blood pressure in patients with end-
stage renal disease was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analysis), PRISMA-P (PRISMA for systematic review protocols), and ROBINS-I (Risk of Bias in Non-Randomized Studies) criteria by
the Cochrane Bias Methods Group. All studies in which the results could have been biased by hemodialysis were excluded. A total
of 14 trials including 412 patients with end-stage renal disease (AVF creation, n=185; AVF ligation, n=227) fulfilled the criteria and
were subsequently analyzed. Average blood pressure in patients with no/closed AVF was 140.5/77.6 mm Hg with a mean arterial
blood pressure of 96.1 mm Hg. Following creation of AVF, systolic blood pressure significantly decreased by 8.7 mm Hg
(P<0.001), diastolic blood pressure by 5.9 mm Hg (P<0.001), and mean arterial blood pressure by 6.6 mm Hg (P=0.02), whereas
after ligation systolic blood pressure increased by 5.2 mm Hg (P=0.07), diastolic blood pressure by 3.8 mm Hg (P=0.02), and
mean arterial blood pressure by 3.7 mm Hg (P=0.07) during short- to long-term follow-up.
Conclusions-—Creation of AVF significantly decreases blood pressure in patients with end-stage renal disease, whereas blood
pressure tends to increase after ligation. These findings illustrate the hemodynamic consequences of AVF which are under
investigation for severe hypertension. ( J Am Heart Assoc. 2019;8:e011183. DOI: 10.1161/JAHA.118.011183.)
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C entral arteriovenous fistula (AVF) creation using a stent-like device (ROX coupler) is under investigation for
treatment of severe resistant hypertension and has been
shown to significantly reduce office and ambulatory 24-hour
blood pressure (BP) when compared with drug treatment
only.1 The principle is based on surgical observations in which
BP variations were documented following surgical AVF
creation, noted almost 100 years ago.2 Surgical creation of
an AVF is often desirable for initiation of hemodialysis in
patients with end-stage renal disease (ESRD), which affects
>1.5 million patients in Europe and the United States.3,4 AVF
exposes the circulation to significant hemodynamic changes
as a consequence of fluid redistribution from the high
pressure, low capacitance arterial to the low pressure, high
capacitance venous system resulting in (1) reduced peripheral
resistance, (2) increased right ventricular preload, and (3) left
ventricular unloading. Although a large number of patients
have undergone AVF creation, the focus so far has mainly
been on adverse hemodynamic effects in ESRD.5–19 Reports
on other clinically relevant variables, particularly BP, are
scarce. Consequently, in addition to a lowering of BP after
AVF creation, an increase in BP may be observed following
AVF ligation.12–19 A systematic meta-analysis on BP effects
following AVF creation/closure has not been reported. Hence,
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we sought to identify and analyze eligible studies in which BP
was recorded before and after creation and ligation of AVF.5–
13,16–20
Methods
The authors declare that all supporting data are available
within the article. This systematic review and meta-analysis
were performed according to the PRISMA, PRISMA-P, and
ROBINS-I (Risk of Bias in Non-Randomized Studies) criteria by
the Cochrane Bias Methods Group.21–24
Study Protocol
A systematic literature search was completed for all peer-
reviewed and published studies which reported office BP
(systolic blood pressure [SBP], diastolic blood pressure [DBP],
and mean arterial blood pressure [MAP]) in patients prior and
after creation/ligation of an AVF, respectively. Studies not
providing valid information on if patients were on hemodial-
ysis while BP was measured have been excluded such as trials
in which the time to the last hemodialysis session remained
unclear, as well as studies with insufficient BP data.
Additionally, only original papers were included; systematic
reviews and case reports were excluded.
Literature Research and Data Extraction
Two investigators (S.S.S., L.L.) searched PubMed, Web of
Science, and the Cochrane Library independently for eligible
studies published until June 2018. The search was performed
using the terms: (((Graft fist*) or (cimin*) or (dialys* shunt*)
or (arterio* fistul*)) and (blood pressure)). The same inves-
tigators screened the search results according to the title and
abstract, reviewed the full-text articles, considered the paper
for inclusion, and extracted appropriate data from the
publications. To ensure comparability of the measurements,
we used only non-invasive office BP measurements, with a
clear relationship to hemodialysis. Measurements were taken
before hemodialysis, on a non-dialysis day, and in patients not
requiring hemodialysis in general, as depicted in Tables 1 and
2. Further details on BP measurement modalities included
automated,6,9–11,18,19 sphygmomanometric,12,13,17,20 and tho-
racic bioimpedance measurements.16 Details on attended/
unattended measurements were not included. If not reported,
corresponding authors were contacted to obtain missing data
on BP values, thereafter effect-size was calculated based on
the available data. Information on BP (SBP, DBP, and MAP),
type of intervention (AVF creation/ligation), heart rate, fistula
flow, age, sex, medication, sample size, and chronic kidney
disease stage were collected.
Assessment of Bias
The bias within and across the studies was further assessed
(Table 3) by the investigators based on the ROBINS-I criteria
in Non-Randomized Studies—of Interventions by the
Cochrane Bias Methods Group (BMG). The overall bias was
judged in reference to the criteria as moderate for all included
studies. In case of disagreements a third investigator (F.M.)
was consulted.
Statistical Analysis
The effects of the intervention (AVF creation/ligation) on BP
(SBP, DBP, and MAP) and heart rate were investigated by
pooling the data (average BP value, standard deviation and
sample size) from each study. Mean differences and pooled
mean differences for SBP, DBP, and MAP were determined
and presented using Forrest plots along with respective 95%
CIs. This was done under the assumption that BP values
before and after AVF creation originate from 2 unmatched
samples. A fixed-, or random-effects model (DerSimonian-
Laird) was used to pool the data, where appropriate.
Statistical heterogeneity between the trials was evaluated
using Cochran Q Test and I2 statistic as a measure of
variability. Relevant statistical heterogeneity was considered
as Cochran Q-Test P<0.05 and I2>50%, in which case a
random-effects was used to estimate the results. Eventual
presence of publication bias was explored visually with Funnel
plots and formally using the Egger regression asymmetry test.
Presence of asymmetry in the Funnel plot was considered as
Clinical Perspective
What Is New?
• This is the first systematic review and meta-analysis further
specifying the effects of arteriovenous fistula creation and
ligation on blood pressure.
• This systematic meta-analysis documented significant
reductions in blood pressure following surgical arteriove-
nous fistula creation and, conversely, blood pressure
increases after arteriovenous fistula ligation in patients with
end-stage renal disease.
What Are the Clinical Implications?
• Owing to the large number of patients with end-stage renal
disease requiring hemodialysis treatment worldwide, the
hemodynamic consequences following arteriovenous fistula
are of importance.
• These data enhance our understanding of the physiological
changes in patients with end-stage renal disease on
hemodialysis and hypertension treatments using a stent-
coupler.
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Table 1. Study characteristics
Author Intervention
BP† (pre-intervention)
(mm Hg)
BP† (post-intervention)
(mm Hg) HR† (bpm)
Shunt flow†
(mL/min) Medication†
Time of
Measurement
(post-
intervention)
Casagrande5 Creation,
n=20
(13 ♂/7 ♀)
155/90/*16/13/* 141/84/*15/8/* 669 vs 669 360160 * 10 d
Utescu6 Creation,
n=31
(20♂/11♀)
132/78/9617/11/12 124/71/8923/12/15 7114 vs 7014 1050410 * 3 mo
Ori7 Creation,
n=10
(5♂/5♀)
154/90/11332/14/21 147/87/10722/11/15 8318 vs 793 250 to 300 2.51.5 vs
2.21.4
13 d
Iwashima8 Creation,
n=16
(11♂/5♀)
159/83/*16/12/* 147/78/*16/12/* 668 vs 668 * No changes 14 d
Korsheed9 Creation,
n=30
(20♂/10♀)
144/75/*28/12/* 134/66/*21/11/* 6011 vs 6011 735600 No changes 2 wks
Vizinho10 Creation,
n=44
(27♂/17♀)
142/79/*16/14/* 132/77/*31/19/* 7711 vs 7812 * No changes 2 mo
Saratzis11 Creation,
n=10
(8♂/2♀)
*/*/98*/*/11 */*/90*/*/12 * 457 to 1350 * 30 d
Kurita12 Ligation,
n=33
(26♂/7♀)
121/67/*22/14/* 126/71/*21/10/* 8413 vs 7713 20001300 1.21.4 vs
1.41.3
7 to 30 d
van Duijnhoven13 Ligation,
n=20
(15♂/5♀)
135/79/*17/7 136/81/*18/10/* 7210 vs 699 1790648 1.81.6 vs
1.71.6
3 to 4 mo
Aitken16 Ligation,
n=100
(51♂/49♀)
*/*/90*/*/17 */*/92*/*/18 9418 vs 8622 965235 No changes 15 min
Velez-Roa17 Ligation,
n=23
(13♂/10♀)
*/*/98*/*18 */*/112*/*/19 7114 vs 6114 * * 30 s
Unger18 Ligation,
n=17
(7♂/10♀)
131/78/9619/15/16 138/85/10314/10/11 7310 vs 688 1371727 * Within
21 mo
Vaes19 Ligation,
n=23; HFS
(10♂/13♀)
111/57*29/19/* 123/63/*29/24/* Decrease by 31 3026705 No changes 15 s
Ligation,
n=11;
HAIDI
(9♂/2♀)
116/48/*30/13/* 122/50/*30/13/* Decrease by 31 1078461
Dundon20 Creation,
n=24
(14♂/10♀)
14619 14617 7112 vs 7611 * * 6 mo
♀ indicates female participants; ♂, male participants; antihypertensive medication (pre vs post); BP, blood pressure (mm Hg); DBP, diastolic blood pressure; HAIDI, hemodialysis access-
induced distal ischemia; HFS, high-flow shunt; HR, heart rate (bpm); MAP, mean blood pressure, values expressed as SBP/DBP/MAPSD, expressed as SDSBP/SDDBP/SDMAP; SBP, systolic
blood pressure; shunt flow (mL/min).
*Not available.
†Values expressed as meanSD.
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the presence of publication bias. In studies not reporting
standard deviation, it was calculated using standard error of
the mean. If within one study more than one measurement
was existing, the measurement with the highest number of
patients and the longest observational period was selected for
the meta-analysis, respectively. Correlation of BP change
(mm Hg) and shunt flow (mL/min) was assessed using
Pearson correlation coefficient (r2). Shunt flow was measured
using dilutional techniques,6,12,13,19 ultrasound,5,9,12,13 and
decrease of CO after compression.18 Shunt flow of the ROX
Coupler was assumed to be 1000 mL/min (800–1000 mL/
min).25 Values are expressed as meanSD. The statistical
analysis was performed using comprehensive meta-analysis
software (CMA). A 2-sided P≤0.05 was considered as
statically significant.
Results
The initial literature search identified 1412 studies from
various databases. After duplicates were removed (n=159),
from the remaining 1253 studies, 21 were identified as
potentially appropriate and eligible for full-text review. Studies
only providing a range of measurements (n=2), those
providing insufficient BP data (n=1), and trials providing
invalid information about the timing of the last hemodialysis
session (n=4) were excluded. A total of 14 studies fulfilled the
criteria (Figure 1) out of which, 11 provided data on SBP
(n=279 patients), 10 on DBP (n=255), and 6 on MAP (n=191
patients), respectively (Figure 2). The final analysis included a
total of 412 patients.
All trials were unblinded, prospective, single-center cohort-
studies, except for 1 retrospective analysis.12 The common
inclusion criteria where age ≥18 years and scheduled for
hemodialysis treatment or ligation of AVF. Common exclusion
criteria were regional wall motion abnormalities, heart
transplantation, congenital heart disease, extreme BP values
(SBP >190 mm Hg, or <80 mm Hg), non-functioning AVF
(after 3 months), stroke, acute coronary syndrome within
3 months of procedure, heart failure and non-sinus-rhythm
(Table 2).
An AVF ligation was performed when patients underwent
kidney transplant, suffered from complications that were
suspected to be caused by the AVF, or the hemodialysis
treatment was terminated. Rarely, other complications (such
as heart failure, swelling of the extremities, cosmetic reasons
etc.) were observed and lead to the ligation of the AVF.
Patient characteristics were representative of ESRD
patients and relatively homogeneous across all studies
(Table 2). However, a lower average patient age was observed
in 2 studies involving AVF ligation. Additionally, more male
(60.4%) than female patients were included. Shunt flow varied
considerably between the studies. The mean shunt flow rateT
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was 725.9474.7 mL/min (P<0.0001), which was provided
by 8 studies (n=285, Table 1). The correlation of shunt flow in
relationship to the observed BP changes are depicted in
Figure 3. Shunt flow correlated with the SBP change
(r2=0.59; P=0.03). Analysis of heart rate showed significant
heterogeneity between the studies (P for Cochran Q=0.00;
I2=99.9%). The extracted data items are summarized in
Tables 1 and 2.
Average SBP, DBP, and MAP were higher in patients
without/closed AVF when compared with open AVF (140.5/
Table 3. Risk of Bias in Non-Randomized Studies
Confounding
Selection of
Participants Classification
Deviations
From
Interventions
Missing
Data
Measurement
of Outcomes
Selective
Reporting
Judgement of
Overall Bias
Casagrande5 PN U PN U PN U N Moderate
Utescu6 PN U PN U PN U PN Moderate
Ori7 PN U PN Y PN PN PN Moderate
Iwashima8 PN U PN N PN PN PN Moderate
Korsheed9 PN U PN Y PY PN PN Moderate
Vizinho10 PN U PN U PY U PN Moderate
Unger18 PN U PN Y PY PN PN Moderate
Kurita12 PN U PN PY PN PN PN Moderate
Duijnhoven13 PN U PN Y PN PN PN Moderate
Aitken16 PN U PN PY PN PN PN Moderate
Velez-Roa17 PN U PN PY PN PN PN Moderate
Saratzis11 PN U PN PN PN PN PN Moderate
Vaes19 PN U PN U PN PN PN Moderate
Dundon20 PN U PN U PN PN PN Moderate
N indicates low; PN, probably low; PY, probably high; U, unclear; Y, high.
Figure 1. PRISMA flow diagram showing search and selection strategies. BP indicates blood pressure
(mm Hg).
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77.6/96.118.8/11.4/15.4 mm Hg versus 136.1/74.7/
91.920/12.1/15.7 mm Hg; all P<0.0001), respectively.
Creation of an AVF lead to a significant reduction in BP
whereas AVF ligation, conversely, increased BP (Figure 2A-C).
After creation of an AVF, SBP was reduced by
8.728.5 mm Hg; P<0.0001 (P for Cochran Q=0.64;
I2=0%), whereas BP tend to increase by 5.229.6 mm Hg;
P=0.07 (P for Cochran Q=0.84; I2=0%) following closure.
Pooling data of patients with closed versus open AVF lead
to a significant reduction of mean SBP (Figure 4A) by
7.428.9 mm Hg; P<0.0001 (P for Cochran Q=0.83;
I2=0%). No sign of significant publication bias (Figure 5) was
observed (Funnel plot SBP, Egger test P=0.97).
After creation of an AVF, DBP was reduced by
5.917.6 mm Hg; P<0.0001 (P for Cochran Q=0.74; I2=0%)
whereas ligation increased DBP by 3.817.23 mm Hg;
P=0.02 (P for Cochran Q=0.91; I2=0%). Mean pooled differ-
ence in DBP (Figure 4B) between the groups closed versus
open AVF resulted in a significant mean difference of
5.017.4 mm Hg; P<0.0001 (P for Cochran Q=0.91;
I2=0%), showing no significant sign of publication bias, as
depicted in Figure 5 (Funnel plot DBP, Egger test P=0.92).
Finally, creation of AVF led to a decrease of MAP (Figure 2C)
by 6.619.4 mm Hg; P=0.02 (P for Cochran Q=0.99; I2=0%)
and ligation to an increase by 3.723.9 mm Hg; P=0.07 (P for
Cochran Q=0.21; I2=35.5%). Pooling the data for MAP resulted
in a significant difference of 4.822.4 mm Hg; P=0.003 (P for
Cochran Q=0.57; I2=0%, Figure 4C).
Figure 3. Correlation of mean SBP (mm Hg) and shunt flow
(mL/min). Values are expressed as mean; r2: coefficient of
determination; Shunt flow in ROX was visualized with 1000 mL/
min (800–1000 mL/min)25 for comparison and not included in
any calculations. BP indicates blood pressure; HAIDI, hemodia-
lysis access-induced distal ischemia; HFS, high-flow shunt; SBP,
systolic blood pressure; Rox: Rox medical coupler.
A
B
C
Figure 2. SBP (A), DBP (B), and MAP (C) difference in mean (mm Hg) AVF creation vs AVF ligation. AVF indicates arteriovenous fistula; relative
weight (%); DBP, diastolic blood pressure; HAIDI, hemodialysis access-induced distal ischemia; HFS, high-flow shunt; MAP, mean blood pressure;
SBP, systolic blood pressure.
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Figure 4. SBP (A), DBP (B), and MAP (C) difference in mean (mm Hg) open vs closed AVF. AVF indicates arteriovenous fistula; relative weight
(%); HAIDI, hemodialysis access-induced distal ischemia; HFS, high-flow shunt; MAP, mean blood pressure; SBP, systolic blood pressure; DBP,
diastolic blood pressure.
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In addition, sensitivity analyses were conducted to
assess potential biological heterogeneity and impact of
time of follow-up. Patient’s age (<60 versus ≥60 years) had
no significant impact on SBP (P for heterogeneity=0.12)
or DBP (P for heterogeneity=0.88, Figure 6), respectively.
Likewise, timing of BP measurement (ultrashort [<1 minute],
short [<30 days] and mid- to long-term [>30 days])
did not impact the BP-lowering effects (P for hetero-
geneity of SBP=0.34, P for heterogeneity of DBP=0.76,
Figure 7).
Figure 5. Funnel plot for SBP (left) and DBP (right). DBP indicates diastolic blood pressure; SBP, systolic blood pressure.
Figure 6. SBP (A) and DBP (B) difference in mean (mm Hg) open vs closed AVF in relationship to patient age (years). AVF indicates
arteriovenous fistula; DBP, diastolic blood pressure; HAIDI, hemodialysis access-induced distal ischemia; HFS, high-flow shunt; SBP, systolic
blood pressure.
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Discussion
Creation of an AVF in patients with ESRD requiring hemodial-
ysis significantly lowered SBP, DBP, and MAP whereas ligation
of an AVF was associated with an increase in BP. These
findings provide novel insights into the hemodynamic conse-
quences of AVF and support the principle of device-based
central iliac AVF creation using a dedicated coupler for
treatment of hypertension.
To the best of our knowledge, comprehensive data on BP
changes following AVF creation however, are lacking. Hence,
this study provides the first systematic review and meta-
analysis, further specifying the effects of AVF creation and
ligation on BP in ESRD. During short- to long-term follow-up
after AVF creation, office SBP significantly decreased by
8.7 mm Hg (P<0.001), DBP by 5.9 mm Hg (P<0.001), and
MAP by 6.6 mm Hg (P=0.02), respectively. Interestingly,
shunt flow correlated with SBP changes during follow-up.
The hypothesis of a clinical meaningful BP reduction following
AVF creation is furthermore supported by the documented BP
increase following ligation, underlining the plausibility of
observed effects (Figure 2).
The consequences of central AVF creation using a 4 mm
stent device (shunt volume 800–1000 mL/min) have
recently been investigated in ROX Control HTN study, an
open-label, multicenter, prospective, randomized, controlled
trial. This study investigated the use of a novel implantable
device (ROX Anastomotic Coupler; ROX Medical Inc, San
Clemente) and documented a significant reduction of mean
24-hour ambulatory BP by 13.5/13.5 mm Hg and office BP
by 26.9/20.1 mm Hg at 6 months follow-up in patients
randomized to the active coupler-treated group with no
indication of secondary BP rise during 12-month follow-
up.1,25 These results indeed support the portrayed BP-
lowering effects after AVF creation in general, whether being
surgically created or device-based.1 The disparity in the
magnitude of the observed BP changes may in part be
related to differences in the underlying diseases (ESRD
Figure 7. SBP (A) and DBP (B) difference in mean (mm Hg) open vs closed AVF in relationship to timing of BP measurements. AVF indicates
arteriovenous fistula; DBP, diastolic blood pressure; HAIDI, hemodialysis access-induced distal ischemia; HFS, high-flow shunt; SBP, systolic
blood pressure.
DOI: 10.1161/JAHA.118.011183 Journal of the American Heart Association 10
Effects of AVF on BP in patients with ESRD Scholz et al
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
D
ow
nloaded from
 http://ahajournals.org by on April 21, 2020
versus resistant hypertension) and the differences in base-
line BP, which were significantly higher in the ROX coupler
study compared with patients included in the present meta-
analysis (175/100 mm Hg versus 140.5/77.6 mm Hg).1
Although the creation of a central AVF using a coupler
effectively lowers BP, one has to keep potential side effects
in mind, i.e. venous stenosis, leg swelling, increased
pulmonary pressure, and right heart dysfunction.1,12,13,18,19
A recently published case report, in which pressure-volume
loops were recorded before and immediately after central
AV-fistula creation, suggests increased cardiac output and
stroke volume following AV-coupling, though with reduced
left ventricular end-diastolic pressure.26
Average baseline BP of the patients included in this meta-
analysis was 140.5/77.6 mm Hg under treatment with
antihypertensive drugs (Table 1), indicating that most of the
patients were diagnosed with hypertension. Both systolic and
diastolic BP decreased following AVF creation by 8.7/
5.9 mm Hg and increased by 5.2/3.8 mm Hg following AVF
ligation, substantiating the plausibility of the observed effects.
It is important to interpret these findings in the context of
cumulating evidence suggesting that even small changes in
BP may correspond to significant improvements in cardiovas-
cular morbidity and mortality in patients with hypertension
and ESRD.27,28 Owing to the large number of patients with
ESRD requiring Hemodialysis treatment worldwide, the eval-
uation of the hemodynamic consequences following AVF is of
importance. The connection of an artery and a vein typically
increases cardiac output, ventricular work, and venous return
to the heart. A recently published, retrospective study of 137
ESRD patients, documented at 2-year follow-up significant
right heart dilatation and deterioration of right heart function,
causing incident heart failure in >40% of the patients.14 These
data suggest, that volume loading from surgically created
shunts may place a major stress on the right heart, causing
remodeling and dysfunction. Some studies indeed suggest
that the incidence of heart failure and mortality are higher in
AVF patients when compared with patients receiving peri-
toneal dialysis.29–31 On the other hand, it has been shown
that creation of an AVF can modestly reduce left ventricular
size, mass, and delay progression of chronic kidney disease in
certain patients.14 However, 1-year results from the ROX
CONTROL Hypertension Trial showed no statistically signifi-
cant change in mean eGFR (estimated glomerular filtration
rate).32
Limitations
The results are limited by the observational nature of the
published studies, which were qualitatively assessed by the
ROBINS I criteria for observational studies. The overall quality
of the included studies was judged as moderate. The analysis
was not preregistered at PROSPERO. There may have been
studies published, in which BP was documented but the word
“blood pressure” was not provided in the title, topic, or key
words. As a result, these studies may not be included in this
meta-analysis. As with all meta-analysis, the risk of potential
publication bias has to be considered when the results are
evaluated. However, no indications for relevant publication
bias could be determined using Funnel plot/Egger regression
asymmetry test. As mentioned, timing of the hemodialysis
and volume status can seriously impact subsequent BP
readings, which caused us to exclude studies with unclear
timing of hemodialysis sessions. The mean number of
antihypertensive drugs remained unchanged over time,
although rigorous assessment of adherence to medication
was not reported, adherence to medication is typically
dynamic and may have affected the BP results. None of the
included studies focused on BP changes primarily, and the
marked variability when follow-up measurements were made
limits our ability to make exact interferences about the timing
of BP changes. To ensure comparability, only office BP
measurements, with a clear relationship to hemodialysis,
taken on a non-dialysis day, and in patients not requiring
hemodialysis in general, entered the analysis. Further details
on BP measurement modalities (automated/semi-automated)
were not available, whereas no study included sufficient
information on whether the measurements were attended/
unattended.
Perspectives
This systematic meta-analysis documented significant reduc-
tions in BP following AVF creation and conversely BP
increases after AVF ligation in patients with ESRD. These
data enhance our understanding of the physiological
changes in patients with ESRD on hemodialysis and provide
the principle of device-based hypertension treatments using
a stent-coupler. Finally, further investigations are necessary
to confirm the documented effects, preferably in random-
ized, masked, controlled studies, using more reliable mea-
sures of BP such as 24-hour BP monitoring, providing
homogeneous data on fistula flow, and long-term outcomes.
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